Yahoo · Oct 9, 2026
Bio-Techne opens GMP small molecule facility in Bristol, UK
The purpose-built site is fully operational and produces materials to support developers working on cell therapies globally.
NASDAQ · TECH
Bio-Techne Corporation
Healthcare · Biotechnology
$72.62
Down-$0.07 (-0.10%)
Updated Oct 24, 2026, 1:13 AM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 9.45B
- P/E ratio
- 120.15
- Dividend yield
- 0.44%
- 52-week range
- $43.20 – $72.69
- Volume
- 4.16M
- Avg. volume
- 2.21M
Price performance · TECH
TECH price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 22, 2026
TECH closed at $72.62 after 20 trading sessions, up 0.01% for the selected period.
- Last close
- $72.62
- Period change
- +0.01%
- Period low
- $72.38
- Period high
- $72.64
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 22, 2026 | $72.56 | $72.69 | $72.5139 | $72.62 | 4.16M |
| Oct 21, 2026 | $72.54 | $72.645 | $72.50 | $72.64 | 3.5M |
| Oct 20, 2026 | $72.48 | $72.61 | $72.48 | $72.58 | 3.21M |
| Oct 19, 2026 | $72.51 | $72.55 | $72.47 | $72.49 | 2.57M |
| Oct 16, 2026 | $72.59 | $72.59 | $72.45 | $72.57 | 2.65M |
| Oct 15, 2026 | $72.53 | $72.61 | $72.50 | $72.52 | 2.4M |
| Oct 14, 2026 | $72.50 | $72.54 | $72.48 | $72.50 | 1.54M |
| Oct 13, 2026 | $72.49 | $72.545 | $72.48 | $72.48 | 2.42M |
| Oct 12, 2026 | $72.47 | $72.585 | $72.44 | $72.56 | 2.42M |
| Oct 9, 2026 | $72.46 | $72.52 | $72.44 | $72.46 | 2.23M |
| Oct 8, 2026 | $72.56 | $72.58 | $72.43 | $72.45 | 5.39M |
| Oct 7, 2026 | $72.43 | $72.55 | $72.43 | $72.53 | 3.15M |
| Oct 6, 2026 | $72.58 | $72.605 | $72.41 | $72.43 | 2.89M |
| Oct 5, 2026 | $72.41 | $72.61 | $72.38 | $72.58 | 2.09M |
| Oct 2, 2026 | $72.44 | $72.47 | $72.38 | $72.40 | 1.87M |
| Oct 1, 2026 | $72.50 | $72.54 | $72.38 | $72.40 | 2.71M |
| Sep 30, 2026 | $72.38 | $72.55 | $72.33 | $72.47 | 3.14M |
| Sep 29, 2026 | $72.36 | $72.50 | $72.36 | $72.38 | 3.36M |
| Sep 28, 2026 | $72.58 | $72.65 | $72.485 | $72.51 | 3.82M |
| Sep 25, 2026 | $72.59 | $72.64 | $72.555 | $72.61 | 2.18M |
Latest TECH news
The latest Smart Investors Daily articles mentioning TECH.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TECH research
Overview
Company profile and research snapshot.
Company profile
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $69.67
- Implied upside
- —
- Analysts
- 23
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Wells Fargo | Equal-Weight | — |
| Jul 9, 2026 | RBC Capital | Sector Perform | — |
| Jun 30, 2026 | Benchmark | Hold | — |
| Jun 30, 2026 | TD Cowen | Hold | — |
| Jun 29, 2026 | Citigroup | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 8, 2026
Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development
Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom, further expanding the company's global capabilities to support the rapidly growing cell therapy market. The investment reflects Bio-Techne's commitment to helping therapy developers address one of the industry's most pressing challenges:
Benzinga · Oct 8, 2026
Bio-Techne Opens New Bristol Facility
Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applicationsNew Bristol facility expands GMP small molecule production capacity and complements recent investments in
Benzinga · Oct 1, 2026
Insider Activity Update: John L Higgins Executes Options Exercise, Resulting In $751K At Bio-Techne
On September 30, it was revealed in an SEC filing that John L Higgins, Director at Bio-Techne (NASDAQ:TECH) executed a significant exercise of company stock options. What Happened: A Form 4 filing with the U.S.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
